Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem Oncology develops and commercializes oncology medicines for RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S. for KRAS-mutated recurrent low-grade serous ovarian cancer and reports commercial updates, product revenue, and medical-conference data for the avutometinib and defactinib combination.
Recurring VSTM news also covers the company’s small-molecule pipeline, including RAF/MEK inhibition, FAK inhibition, and VS-7375, an oral KRAS G12D inhibitor studied in KRAS G12D-mutant solid tumors. Company updates commonly include clinical-trial analyses from RAMP studies, preclinical research presentations, FDA-related treatment context, patient advocacy resources for LGSOC, executive and employee equity grants, and quarterly financial results.
Verastem Oncology (Nasdaq: VSTM) reported Q2 2025 financial results and significant business updates. The company achieved $2.1 million in net product revenue from AVMAPKI FAKZYNJA CO-PACK in its first six weeks following FDA approval for KRAS-mutated recurrent low-grade serous ovarian cancer. The company ended Q2 with $164.3 million in cash, providing runway into H2 2026.
Key highlights include the first patient dosed in the VS-7375 Phase 1/2a trial for KRAS G12D advanced solid tumors, Fast Track Designation for VS-7375, and positive updated data from the RAMP 205 trial in metastatic pancreatic cancer showing 83% overall response rate. Q2 financial results showed a net loss of $25.9 million, or $0.39 per share, with total operating expenses of $45.9 million.
The company continues to advance multiple clinical programs, including the Phase 3 RAMP 301 trial nearing completion of planned enrollment and expansion of the VS-7375 trial with four new cohorts.
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company focused on RAS/MAPK pathway-driven cancer treatments, will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, August 7, 2025, at 4:30 PM ET.
Investors can access the call by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) with passcode 1210516. The webcast and presentation slides will be available on the company's investor relations website, with a replay available after the event.
Verastem Oncology (Nasdaq: VSTM) has received Fast Track Designation (FTD) from the FDA for VS-7375, its oral KRAS G12D inhibitor, for treating KRAS G12D-mutated pancreatic cancer in both first-line and previously treated settings.
VS-7375 is currently being evaluated in a U.S. Phase 1/2a clinical trial, with plans for global expansion. The study began at a 400mg QD dose, based on efficacy data from GenFleet Therapeutics' China trial. The trial will assess the drug as monotherapy in pancreatic and non-small cell lung cancer, and in combination with cetuximab for advanced solid tumors, including colorectal cancer.
Notably, the KRAS G12D mutation affects 37% of pancreatic cancers and is the most prevalent KRAS mutation in human cancers. Initial safety and efficacy results from GenFleet's Phase 1 study were presented at ASCO 2025.
Verastem Oncology (Nasdaq: VSTM) announced the publication of primary results from its Phase 2 RAMP 201 trial in the Journal of Clinical Oncology, evaluating avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
The study demonstrated significant efficacy with an overall response rate of 31% across all patients, with particularly strong results in KRAS-mutant patients (44% ORR) compared to KRAS wild-type (17% ORR). The median progression-free survival was 12.9 months overall, extending to 22.0 months in KRAS-mutant patients. Notably, 82% of patients showed tumor reduction regardless of KRAS mutation status.
The combination therapy showed a favorable safety profile with only 10% discontinuation rate due to adverse events. The most common side effects included nausea (67%), increased creatine phosphokinase levels (60%), and diarrhea (58.3%).
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company focused on RAS/MAPK pathway-driven cancer treatments, has granted stock options to four new employees. The inducement grants, issued under Nasdaq Listing Rule 5635(c)(4), consist of options to purchase 45,000 shares of common stock at an exercise price of $4.29 per share.
The options will vest over four years, with 25% vesting on the one-year employment anniversary and the remaining vesting quarterly over three years, subject to continued service with the company.
Verastem Oncology (Nasdaq: VSTM) announced the publication of updated results from their Phase 1 FRAME study in Nature Medicine, evaluating the combination of avutometinib and defactinib in solid tumors, particularly low-grade serous ovarian cancer (LGSOC).
The study demonstrated significant efficacy with an overall response rate (ORR) of 42.3% and median progression-free survival (mPFS) of 20.1 months in LGSOC patients. For patients with KRAS mutations, the results were even more promising, showing an ORR of 58.3% and mPFS of 30.8 months. In patients without KRAS mutations, the ORR was 33.3% with 8.9 months mPFS.
The safety profile was favorable, with only 4% of LGSOC patients discontinuing treatment due to adverse events. The most common side effects included rash (90%), elevated creatine phosphokinase (56%), AST elevation (43%), hyperbilirubinemia (38%), and diarrhea (38%). The study, conducted by the Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, established the foundation for the recent FDA approval of this combination therapy in KRAS-mutated recurrent LGSOC.
Verastem Oncology (Nasdaq: VSTM) has announced the dosing of its first patient in a U.S. Phase 1/2a clinical trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, targeting advanced KRAS G12D mutant solid tumors.
The trial, VS-7375-101, will begin with a monotherapy dose escalation phase starting at 400 mg, based on efficacious dosing from GenFleet Therapeutics' China study. The company plans to expand into monotherapy cohorts for pancreatic cancer and non-small cell lung cancer, while simultaneously evaluating VS-7375 in combination with cetuximab for colorectal cancer.
This milestone follows Verastem's recent FDA approval, commercial launch, and positive results in first-line metastatic pancreatic cancer treatment.
Verastem Oncology (VSTM), a biopharmaceutical company focused on developing treatments for RAS/MAPK pathway-driven cancers, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management team will engage in a fireside chat on June 4, 2025, at 4:20 pm ET in New York. Investors and interested parties can access a live webcast of the presentation through the "Events & Presentations" section of Verastem's website, with a replay available for approximately 90 days afterward.